Quetiapine XR: Current status for the treatment of major depressive disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 7, 2010, Pages 1165-1173

  Pae, Chi Un ^a,b   Sohi, Manmohandeep Singh ^b   Seo, Ho Jun ^a   Serretti, Alessandro ^c   Patkar, Ashwin A ^b   Steffens, David C ^b   Masand, Prakash S ^b  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Major depressive disorder; Quetiapine XR

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DULOXETINE; ESCITALOPRAM; NORQUETIAPINE; PLACEBO; QUETIAPINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ABNORMAL DREAMING; ADD ON THERAPY; ADJUVANT THERAPY; AKATHISIA; ANXIETY; ARTHRALGIA; BACKACHE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERSOMNIA; HYPERTRIGLYCERIDEMIA; INCREASED APPETITE; INFLUENZA; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MONOTHERAPY; MYALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; POLLAKISURIA; PULSE RATE; REMISSION; RESTLESSNESS; REVIEW; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; HUMANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956421518     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.03.023     Document Type: Review

References (46)

1. Altschuler E.L., Kast R.E. Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses 2005, 65:65-67.
2. AstraZeneca Pharaceuticals I. D1448C00004. A multi-centre, double-blind, randomised, parallel group, placebo-controlled and active controlled phase III study of the efficacy and safety of quetiapine fumarate extended release (SEROQUEL XR™) as mono-therapy in the treatment of adult patients with major depressive disorder (Amber study).
3. AstraZeneca Pharaceuticals I. D1448C00005. A multicenter, double-blind, randomized-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate extended release (SEROQUEL XR™) as monotherapy in the maintenance treatment of patients with major depressive disorder following an open-label stabilization period (Amethyst study).
4. AstraZeneca Pharmaceuticals D1448C00003. A multicenter, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate extended release (SEROQUEL XR) as mono-therapy in the treatment of adult patients with major depressive disorder (Opal study).
5. AstraZeneca Pharmaceuticals Inc. http://www.astrazenecaclinicaltrials.com/.
6. Bauer M., Pretorius H.W., Constant E.L., Earley W.R., Szamosi J., Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009, 70:540-549.
7. Baune B.T., Caliskan S., Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007, 22:1-9.
8. Cruz N., Sanchez-Moreno J., Torres F., Goikolea J.M., Valenti M., Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2009, 1-10.
9. Cutler A.J., Montgomery S.A., Feifel D., Lazarus A., Astrom M., Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009, 70:526-539.
10. de Borja Goncalves Guerra A., Castel S., Benedito-Silva A.A., Calil H.M. Neuroendocrine effects of quetiapine in healthy volunteers. Int J Neuropsychopharmacol 2005, 8:49-57.
11. El-Khalali N., Joyce M., Atkinson S., Buynak R.J., Datto C., Lindgren P., et al. Extended release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment - a multicenter, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010, 13:917-932.
12. Endicott J., Paulsson B., Gustafsson U., Schioler H., Hassan M. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord 2008, 111:306-319.
13. Figueroa C., Brecher M., Hamer-Maansson J.E., Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:199-204.
14. Fleurence R., Williamson R., Jing Y., Kim E., Tran Q.V., Pikalov A.S., et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009, 42:57-90.
15. Gao K., Ganocy S.J., Gajwani P., Muzina D.J., Kemp D.E., Calabrese J.R. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008, 69:302-309.
16. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001, 76:1521-1531.
17. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002, 956:349-357.
18. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., Roth B.L. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33:2303-2312.
19. Kennedy S.H., Lam R.W., Cohen N.L., Ravindran A.V. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001, 46(Suppl 1):38S-58S.
20. Lammers C.H., Diaz J., Schwartz J.C., Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000, 5:378-388.
21. Licinio J., Wong M.L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999, 4:317-327.
22. Lieberman J.A. Comparative effectiveness of antipsychotic drugs. A commentary on: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) and clinical antipsychotic trials of intervention effectiveness (CATIE). Arch Gen Psychiatry 2006, 63:1069-1072.
23. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
24. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
25. Musselman D.L., Betan E., Larsen H., Phillips L.S. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003, 54:317-329.
26. Naber D., Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009, 23:649-659.
27. Nierenberg A.A., McLean N.E., Alpert J.E., Worthington J.J., Rosenbaum J.F., Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995, 152:1500-1503.
28. Nyberg S., Takano A., Grimm S., Gulyas B., McCarthy D., Lee C., et al. PET-measured D2, 5-HT2, and norepinephrine transporter (NET) occupancy by quetiapine and N-desalkyl-quetiapine in non-human primates. Eur Neuropsychopharmacol 2007, 17:S254-S255.
29. Olver J.S., Ignatiadis S., Maruff P., Burrows G.D., Norman T.R. Quetiapine augmentation in depressed patients with partial response to antidepressants. Hum Psychopharmacol 2008, 23:653-660.
30. Pae C.U., Serretti A., Patkar A.A., Masand P.S. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008, 22:367-388.
31. Papakostas G.I., Petersen T., Sklarsky K.G., Nierenberg A.A., Alpert J.E., Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res 2007, 149:195-200.
32. Perlis R.H. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am J Manag Care 2007, 13:S178-S188.
33. Pira L., Mongeau R., Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur J Pharmacol 2004, 504:61-64.
34. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225-235.
35. Rush A.J., Giles D.E., Schlesser M.A., Orsulak P.J., Parker C.R., Weissenburger J.E., et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 1996, 57:470-484.
36. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
37. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
38. Stahl S.M. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998, 59(Suppl 4):5-14.
39. Stephenson C.M., Bigliani V., Jones H.M., Mulligan R.S., Acton P.D., Visvikis D., et al. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study. Br J Psychiatry 2000, 177:408-415.
40. Suppes T., Dennehy E.B., Hirschfeld R.M., Altshuler L.L., Bowden C.L., Calabrese J.R., et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005, 66:870-886.
41. Tarazi F.I., Zhang K., Baldessarini R.J. Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neurosci Lett 2000, 287:81-84.
42. Tascedda F., Lovati E., Blom J.M., Muzzioli P., Brunello N., Racagni G., et al. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 1999, 21:211-217.
43. U.S. Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.Supplements&#totable.
44. Weisler R., Joyce M., McGill L., Lazarus A., Szamosi J., Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009, 14:299-313.
45. Xu H., Wang H., Zhuang L., Yan B., Yu Y., Wei Z., et al. Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer's disease. FEBS J 2008, 275:3718-3728.
46. Yatham L.N., Goldstein J.M., Vieta E., Bowden C.L., Grunze H., Post R.M., et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005, 66(Suppl 5):40-48.